Literature DB >> 21145259

HLA mismatches influence lung transplant recipient survival, bronchiolitis obliterans and rejection: implications for donor lung allocation.

Matthias Peltz1, Leah B Edwards, Michael E Jessen, Fernando Torres, Dan M Meyer.   

Abstract

BACKGROUND: Human leukocyte antigen (HLA) histocompatibility is not considered when placing donor allografts for lung transplantation. We previously reported that fewer individual Class I (HLA-A and -B) and Class II (HLA-DR) antigen mismatches (MM) correlated with improved survival in lung transplant recipients. In this study we evaluated whether the effects of total HLA, Class I and Class II MM were more important determinants of: (1) recipient survival; (2) development of bronchiolitis obliterans (BO); and (3) freedom from acute rejection (AR).
METHODS: All adult primary cadaveric lung recipients transplanted between April 1, 1994, and June 30, 2004 entered in the OPTN database were included (n = 9,791). Groups were created based on the total number of HLA, Class I and Class II MM. Recipient survival, freedom from AR and freedom from BO were compared. Univariate data were computed using the Kaplan-Meier method and compared by log-rank test. Multivariate analysis was performed using the Cox proportional hazards method.
RESULTS: Univariate analysis identified significantly improved survival in recipients with fewer total HLA (p < 0.001) and Class I MM (p = 0.005). The incidence of BO was significantly lower in patients with fewer total Class I MM (p = 0.036). AR was influenced only by Class II MM (p = 0.005). By multivariate analysis, total HLA, Class I and Class II MM impacted recipient survival. Total HLA and Class I MM correlated with development of BO. Class II MM correlated with development of AR.
CONCLUSION: HLA MM are important determinants of lung transplant survival, BO and AR. These data suggest that donor-recipient HLA MM may warrant consideration when allocating organs for lung transplantation.
Copyright © 2011 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21145259     DOI: 10.1016/j.healun.2010.10.005

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  13 in total

1.  Influence of HLA Mismatching on Survival in Lung Transplantation.

Authors:  Don Hayes; Bryan A Whitson; Samir N Ghadiali; Joseph D Tobias; Heidi M Mansour; Sylvester M Black
Journal:  Lung       Date:  2015-07-29       Impact factor: 2.584

2.  Purinergic P2X4 receptors and mitochondrial ATP production regulate T cell migration.

Authors:  Carola Ledderose; Kaifeng Liu; Yutaka Kondo; Christian J Slubowski; Thomas Dertnig; Sara Denicoló; Mona Arbab; Johannes Hubner; Kirstin Konrad; Mahtab Fakhari; James A Lederer; Simon C Robson; Gary A Visner; Wolfgang G Junger
Journal:  J Clin Invest       Date:  2018-07-23       Impact factor: 14.808

3.  Risk Factors for Acute Rejection in the First Year after Lung Transplant. A Multicenter Study.

Authors:  Jamie L Todd; Megan L Neely; Heather Kopetskie; Michelle L Sever; Jerry Kirchner; Courtney W Frankel; Laurie D Snyder; Elizabeth N Pavlisko; Tereza Martinu; Wayne Tsuang; Michael Y Shino; Nikki Williams; Mark A Robien; Lianne G Singer; Marie Budev; Pali D Shah; John M Reynolds; Scott M Palmer; John A Belperio; S Sam Weigt
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

4.  Validation of a Simple, Rapid, and Cost-Effective Method for Acute Rejection Monitoring in Lung Transplant Recipients.

Authors:  Monica Sorbini; Gabriele Togliatto; Fiorenza Mioli; Erika Simonato; Matteo Marro; Margherita Cappuccio; Francesca Arruga; Cristiana Caorsi; Morteza Mansouri; Paola Magistroni; Alessandro Gambella; Luisa Delsedime; Mauro Giulio Papotti; Paolo Solidoro; Carlo Albera; Massimo Boffini; Mauro Rinaldi; Antonio Amoroso; Tiziana Vaisitti; Silvia Deaglio
Journal:  Transpl Int       Date:  2022-06-09       Impact factor: 3.842

5.  Role of Circulating MicroRNAs in the Immunopathogenesis of Rejection After Pediatric Lung Transplantation.

Authors:  Zhongping Xu; Wei Yang; Nancy Steward; Stuart C Sweet; Lara Danziger-Isakov; Peter S Heeger; Thalachallour Mohanakumar
Journal:  Transplantation       Date:  2017-10       Impact factor: 4.939

6.  Pre-transplant Panel Reactive Antibody and Survival in Adult Cystic Fibrosis Patients After Lung Transplantation.

Authors:  Don Hayes; Dmitry Tumin; Joseph D Tobias
Journal:  Lung       Date:  2016-03-02       Impact factor: 2.584

7.  Mechanistic differences between phenotypes of chronic lung allograft dysfunction after lung transplantation.

Authors:  Monika I Suwara; Bart M Vanaudenaerde; Stijn E Verleden; Robin Vos; Nicola J Green; Chris Ward; Lee A Borthwick; Elly Vandermeulen; Jim Lordan; Dirk E Van Raemdonck; Paul A Corris; Geert M Verleden; Andrew J Fisher
Journal:  Transpl Int       Date:  2014-06-17       Impact factor: 3.782

8.  Prevalence of pre-transplant anti-HLA antibodies and their impact on outcomes in lung transplant recipients.

Authors:  Ji Eun Park; Chi Young Kim; Moo Suk Park; Joo Han Song; Young Sam Kim; Jin Gu Lee; Hyo Chae Paik; Song Yee Kim
Journal:  BMC Pulm Med       Date:  2018-03-12       Impact factor: 3.317

9.  HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation.

Authors:  Shehnaz K Hussain; Solomon B Makgoeng; Matthew J Everly; Marc T Goodman; Otoniel Martínez-Maza; Lindsay M Morton; Christina A Clarke; Charles F Lynch; Jon Snyder; Ajay Israni; Bertram L Kasiske; Eric A Engels
Journal:  Transplantation       Date:  2016-11       Impact factor: 5.385

10.  Practical guidelines: lung transplantation in patients with cystic fibrosis.

Authors:  T O Hirche; C Knoop; H Hebestreit; D Shimmin; A Solé; J S Elborn; H Ellemunter; P Aurora; M Hogardt; T O F Wagner
Journal:  Pulm Med       Date:  2014-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.